Related Experiment Videos
Co-stimulation: novel methods for preventing viral-induced lung inflammation
Tracy Hussell1, Robert Snelgrove, Ian R Humphreys
1Centre for Molecular Microbiology and Infection, Lord Flowers Building, Imperial College of Science, Technology and Medicine, Exhibition Road, London SW7 2AZ, UK. t.hussell@iperial.ac.uk
Trends in Molecular Medicine
|August 18, 2004
Summary
Targeting immune cells like OX40 and 4-1BB offers new ways to treat lung inflammation from viral infections. Recent research shows inhibiting OX40 benefits influenza, suggesting potential for broader immune intervention in respiratory diseases.
Area of Science:
- Immunology
- Pulmonology
- Virology
Background:
- Respiratory infections lead to significant global morbidity and mortality.
- While the immune response is crucial for pathogen clearance, excessive inflammation can harm lung tissue and function.
- Existing immune interventions often lack specificity, targeting broadly rather than antigen-specific immune cells.
Purpose of the Study:
- To review recent advances in manipulating immune molecules like OX40 and 4-1BB.
- To explore the application of these manipulations in treating viral lung inflammatory conditions.
- To highlight the potential of targeted immune interventions for respiratory diseases.
Main Methods:
- Review of recent scientific literature on T-cell activation pathways.
- Analysis of studies investigating OX40 and 4-1BB receptor family members.
- Examination of therapeutic strategies involving immune cell modulation in viral infections.
Main Results:
- OX40 and 4-1BB are tumor necrosis factor receptor family members expressed on T cells during inflammation.
- Inhibition of OX40 has demonstrated efficacy in managing influenza virus infections.
- These findings suggest a potential for targeted immune intervention in viral lung diseases.
Conclusions:
- Targeting specific immune molecules offers a promising approach to managing inflammatory lung conditions.
- Modulation of OX40 and 4-1BB presents a potential therapeutic avenue for viral respiratory infections.
- Further research into targeted immune interventions could reduce morbidity and mortality associated with lung infections.